Drug intelligence / Profile preview

MBP431

Development stage
Unknown
Lead developer
Mapp Biopharmaceutical
Modality
Monoclonal Antibodies → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

MBP431 is an experimental monoclonal antibody cocktail developed by MAPP Biopharmaceuticals specifically for the treatment of Ebola virus disease caused by the Sudan virus (SUDV). The cocktail is composed of two potent, neutralizing human monoclonal antibodies, mAb282 and mAb322, which were originally identified from survivors of Sudan virus infections. These antibodies target non-overlapping epitopes on the Sudan virus glycoprotein (GP), working synergistically to neutralize the virus and block its entry into host cells. Developed with significant support from the Biomedical Advanced Research and Development Authority (BARDA), MBP431 has undergone Phase 1 clinical evaluation and was deployed for compassionate use during the 2022 Sudan virus outbreak in Uganda.

Other names
Sudan virus monoclonal antibody cocktailSUDV mAb cocktailSudan ebolavirus mAb cocktail
02

Targets

BDBV GP (Bundibugyo ebolavirus glycoprotein)Zaire ebolavirus glycoprotein

Beyond the preview

Go deeper on MBP431.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on MBP431.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call